Clinical significance of microRNA-200 and let-7 families expression assessment in patients with ovarian cancer

被引：9

作者：

Ferneza, Severyn ^{[1
]}

Fetsych, Markiyan ^{[1
]}

Shuliak, Roman ^{[2
]}

Makukh, Halyna ^{[3
]}

Volodko, Natalia ^{[1
]}

Yarema, Roman ^{[1
]}

Fetsych, Taras ^{[1
]}

机构：

[1] Danylo Halytsky Lviv Natl Med Univ, Dept Oncol & Radiol FPGE, Hasheka 2A Str, UA-79000 Lvov, Ukraine

[2] Lviv State Reg Oncol Treatment & Diagnost Ctr, Dept Microinvas Surg, Hasheka 2A Str, UA-79000 Lvov, Ukraine

[3] Natl Acad Med Sci Ukraine, Inst Hereditary Pathol, UA-79000 Lvov, Ukraine

来源：

ECANCERMEDICALSCIENCE | 2021年 / 15卷

关键词：

microRNA; ovarian cancer; biomarkers; MIR-200; FAMILY; SENSITIVITY; PACLITAXEL; BIOMARKERS; RESISTANCE; CARCINOMA; CHEMORESISTANCE; PROLIFERATION; INVASIVENESS; PHENOTYPE;

D O I：

10.3332/ecancer.2021.1249

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Ovarian cancer (OC) represents the most lethal malignancy in gynaecologic oncology practice and shows a high recurrence rate due to its early chemoresistance to first-line chemotherapy. Yet, timely selection of the correct treatment strategy is likely to prolong a patient's survival. MicroRNAs (miRNAs) are a class of short non-coding RNAs responsible for the expression of 30%-60% of human genes. In numerous studies, miRNAs have been used to provide the overall prognosis for patients and analyse the process's prevalence and responses to chemotherapy. In particular, miRNAs as markers for predicting the sensitivity of OC to platinum- and taxane-based chemotherapeutics can significantly improve the treatment efficacy. This article highlights two families of miRNAs: miR-200 and let-7, which are promising for further research on OC and its chemosensitivity.

引用

页数：17

共 64 条

[1] Integrated genomic analyses of ovarian carcinoma [J].

Bell, D. ;

Berchuck, A. ;

Birrer, M. ;

Chien, J. ;

Cramer, D. W. ;

Dao, F. ;

Dhir, R. ;

DiSaia, P. ;

Gabra, H. ;

Glenn, P. ;

Godwin, A. K. ;

Gross, J. ;

Hartmann, L. ;

Huang, M. ;

Huntsman, D. G. ;

Iacocca, M. ;

Imielinski, M. ;

Kalloger, S. ;

Karlan, B. Y. ;

Levine, D. A. ;

Mills, G. B. ;

Morrison, C. ;

Mutch, D. ;

Olvera, N. ;

Orsulic, S. ;

Park, K. ;

Petrelli, N. ;

Rabeno, B. ;

Rader, J. S. ;

Sikic, B. I. ;

Smith-McCune, K. ;

Sood, A. K. ;

Bowtell, D. ;

Penny, R. ;

Testa, J. R. ;

Chang, K. ;

Dinh, H. H. ;

Drummond, J. A. ;

Fowler, G. ;

Gunaratne, P. ;

Hawes, A. C. ;

Kovar, C. L. ;

Lewis, L. R. ;

Morgan, M. B. ;

Newsham, I. F. ;

Santibanez, J. ;

Reid, J. G. ;

Trevino, L. R. ;

Wu, Y. -Q. ;

Wang, M. .

NATURE, 2011, 474 (7353) :609-615

[2] MicroRNA Expression in Formalin-fixed Paraffin-embedded Cancer Tissue: Identifying Reference MicroRNAs and Variability [J].

Boisen, Mogens Karsbol ;

Dehlendorff, Christian ;

Linnemann, Dorte ;

Schultz, Nicolai Aagaard ;

Jensen, Benny Vittrup ;

Hogdall, Estrid Vilma Solyom ;

Johansen, Julia Sidenius .

BMC CANCER, 2015, 15

[3] Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1 [J].

Boyerinas, Benjamin ;

Park, Sun-Mi ;

Murmann, Andrea E. ;

Gwin, Katja ;

Montag, Anton G. ;

Zillhardt, Marion ;

Hua, You-Jia ;

Lengyel, Ernst ;

Peter, Marcus E. .

INTERNATIONAL JOURNAL OF CANCER, 2012, 130 (08) :1787-1797

[4] The miR-200 family differentially regulates sensitivity to paclitaxel and carboplatin in human ovarian carcinoma OVCAR-3 and MES-OV cells [J].

Brozovic, Anamaria ;

Duran, George E. ;

Wang, Yan C. ;

Francisco, E. Brian ;

Sikic, Branimir I. .

MOLECULAR ONCOLOGY, 2015, 9 (08) :1678-1693

[5]

Cao Q, 2014, INT J CLIN EXP PATHO, V7, P2392

[6] Characterization of miR-200 family members as blood biomarkers for human and laying hen ovarian cancer [J].

Choi, Pui-Wah ;

Bahrampour, Abbas ;

Ng, Shu-Kay ;

Liu, Sze Kei ;

Qiu, Wei ;

Xie, Fang ;

Kuo, Winston Patrick ;

Kwong, Joseph ;

Hales, Karen H. ;

Hales, Dale B. ;

Wong, Kwong-Kwok ;

Norwitz, Errol R. ;

Chow, Chun Kin ;

Berkowitz, Ross S. ;

Ng, Shu-Wing .

SCIENTIFIC REPORTS, 2020, 10 (01)

[7]

Chung YW, 2013, INT J GYN CAN, V23

[8] Restoration of miR-200c to Ovarian Cancer Reduces Tumor Burden and Increases Sensitivity to Paclitaxel [J].

Cittelly, Diana M. ;

Dimitrova, Irina ;

Howe, Erin N. ;

Cochrane, Dawn R. ;

Jean, Annie ;

Spoelstra, Nicole S. ;

Post, Miriam D. ;

Lu, Xian ;

Broaddus, Russell R. ;

Spillman, Monique A. ;

Richer, Jennifer K. .

MOLECULAR CANCER THERAPEUTICS, 2012, 11 (12) :2556-2565

[9] International patterns and trends in ovarian cancer incidence, overall and by histologic subtype [J].

Coburn, S. B. ;

Bray, F. ;

Sherman, M. E. ;

Trabert, B. .

INTERNATIONAL JOURNAL OF CANCER, 2017, 140 (11) :2451-2460

[10] Loss of miR-200c: A Marker of Aggressiveness and Chemoresistance in Female Reproductive Cancers [J].

Cochrane, Dawn R. ;

Howe, Erin N. ;

Spoelstra, Nicole S. ;

Richer, Jennifer K. .

JOURNAL OF ONCOLOGY, 2010, 2010

← 1 2 3 4 5 6 7 →